Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian …
S Ramagopalan, V Allan, S Saragoni… - Journal of …, 2018 - becarispublishing.com
Aim: This study aimed to evaluate the risk of major bleeding among two cohorts of
nonvalvular atrial fibrillation patients newly initiating a vitamin K antagonist (VKA) or …
nonvalvular atrial fibrillation patients newly initiating a vitamin K antagonist (VKA) or …
Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian …
S Ramagopalan, V Allan, S Saragoni… - Journal of …, 2018 - europepmc.org
Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with
apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases …
apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases …
Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian …
S Ramagopalan, V Allan, S Saragoni… - Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Aim This study aimed to evaluate the risk of major bleeding among two cohorts of
nonvalvular atrial fibrillation patients newly initiating a vitamin K antagonist (VKA) or …
nonvalvular atrial fibrillation patients newly initiating a vitamin K antagonist (VKA) or …